{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:37:28Z","timestamp":1757543848902},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,8,30]],"date-time":"2005-08-30T00:00:00Z","timestamp":1125360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1002\/pds.1145","type":"journal-article","created":{"date-parts":[[2005,8,30]],"date-time":"2005-08-30T16:20:07Z","timestamp":1125418807000},"page":"611-613","source":"Crossref","is-referenced-by-count":3,"title":["Isotretinoin prescribing: finding a balance between benefit and risk"],"prefix":"10.1002","volume":"14","author":[{"given":"Robert S.","family":"Stern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,30]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197902153000701"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(84)80142-5"},{"key":"e_1_2_1_4_2","first-page":"1","article-title":"Anti\u2010acne drug faulted in birth defects","author":"Kolata G","year":"1988","journal-title":"N Y Times"},{"key":"e_1_2_1_5_2","first-page":"39","article-title":"Maternal exposure to accutane","author":"Graham DJ","year":"1998","journal-title":"Position paper"},{"key":"e_1_2_1_6_2","unstructured":"Department of Health and Human Services.Food and Drug Administration Center for Drug Evaluation and Research.1998; NDA 18\u2013662."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1111"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.110901"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.10.1231"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.5.557"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.5.563"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507133330206"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70135-3"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88289-2"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198904133201510"},{"key":"e_1_2_1_16_2","unstructured":"Testimony of David J. Graham MD MPH November 18 2004 to US Congressional Committee.2004;1\u20136."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1145","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:28:22Z","timestamp":1696638502000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,30]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1002\/pds.1145"],"URL":"https:\/\/doi.org\/10.1002\/pds.1145","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,30]]}}}